Neue Entwicklungen bei der Behandlung atopischer Hunde

Die atopische Dermatitis (AD) beim Hund kommt in der Kleintierpraxis sehr häufig vor. Im Rahmen dieses Artikels werden die bisherigen Behandlungsoptionen, die neuen Therapieansätze sowie das Management der atopischen Patienten und deren Besitzer ausführlich beschrieben.

• Literatur

• 1 Saridomichelakis MN, Olivry T. An update on the treatment of canine atopic dermatitis. Vet J 2016; 207: 29-37
• 2 Saridomichelakis MN, Koutinas AF, Gioulekas D. et al. Canine atopic dermatitis in Greece: clinical observations and the prevalence of positive intradermal test reactions in 91 spontaneous cases. Vet Immunol Immunopathol 1999; 69 (01) 61-73
• 3 Olivry T, Mueller RS. International Task Force on Canine Atopic D. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003; 14 (03) 121-146
• 4 Olivry T, DeBoer DJ, Favrot C. et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 2015; 11: 210
• 5 Nuttall T, Mueller R, Bensignor E. et al. Efficacy of a 0.0584 % hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol 2009; 20 (03) 191-198
• 6 Nuttall TJ, McEwan NA, Bensignor E. et al. Comparable efficacy of a topical 0.0584 % hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. Vet Dermatol 2012; 23 (01) 4-10 e1–2
• 7 Marsella R, Nicklin CF, Saglio S. et al. Investigation on the clinical efficacy and safety of 0.1 % tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol 2004; 15 (05) 294-303
• 8 Bensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol 2005; 16 (01) 52-60
• 9 Saevik BK, Bergvall K, Holm BR. et al. A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Vet Dermatol 2004; 15 (03) 137-145
• 10 Muller MR, Linek M, Lowenstein C. et al. Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis. Vet J 2016; 210: 77-81
• 11 Olivry T, DeBoer DJ, Favrot C. et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010; 21 (03) 233-248
• 12 DeBoer DJ, Griffin CE. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Vet Immunol Immunopathol 2001; 81(3 – 4): 323-329
• 13 Bizikova P, Papich MG, Olivry T. Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. Vet Dermatol 2008; 19 (06) 348-357
• 14 Eichenseer M, Johansen C, Mueller RS. Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double-blinded trial. Vet Rec 2013; 173 (17) 423
• 15 Steffan J, Parks C, Seewald W. North American Veterinary Dermatology Cyclosporine Study G. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc 2005; 226 (11) 1855-1863
• 16 Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Vet Rec 2014; 174 Suppl 2: 3-12
• 17 Kovalik M, Thoday KL, van den Broek AH. The use of ciclosporin A in veterinary dermatology. Vet J 2012; 193 (02) 317-325
• 18 Gonzales AJ, Bowman JW, Fici GJ. et al. Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 2014; 37 (04) 317-324
• 19 Little PR, King VL, Davis KR. et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 2015; 26 (01) 23-30 e7–8
• 20 Cosgrove SB, Wren JA, Cleaver DM. et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24 (06) 587-597 e141–142
• 21 Cosgrove SB, Cleaver DM, King VL. et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol 2015; 26 (03) 171-179 e35
• 22 Simpson AC, Schissler JR, Rosychuk RAW. et al. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study. Vet Dermatol 2017; 28 (05) 485-e113
• 23 Fukuyama T, Ganchingco JR, Baumer W. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib. Eur J Pharmacol 2017; 794: 20-26
• 24 Gadeyne C, Little P, King VL. et al. Efficacy of oclacitinib (Apoquel(R)) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol 2014; 25 (06) 512-518 e86
• 25 McCandless EE, Rugg CA, Fici GJ. et al. Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells. Vet Immunol Immunopathol 2014; 157(1 – 2): 42-48
• 26 Michels GM, Ramsey DS. et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 2016; 27 (06) 478-e129
• 27 Marsella R, Ahrens K, Sanford R. Investigation of the correlation of serum IL-31 with severity of dermatitis in an experimental model of canine atopic dermatitis using beagle dogs. Vet Dermatol 2018; 29 (01) 69-e28
• 28 Michels GM, Walsh KF, Kryda KA. et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol 2016; 27 (06) 505-e136
• 29 Moyaert H, Van Brussel L, Borowski S. et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol 2017; 28 (06) 593-e145
• 30 Bachmann MF, Zeltins A, Kalnins G. et al. Vaccination against IL-31 for the treatment of atopic dermatitis in dogs. J Allergy Clin Immunol 2018; 142 (01) 279-281.e1
• 31 Klinger CJ, Hobi S, Johansen C. et al. Vitamin D shows in vivo efficacy in a placebo-controlled, double-blinded, randomised clinical trial on canine atopic dermatitis. Vet Rec 2018; 182 (14) 406
• 32 Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol 2009; 20 (02) 84-98
• 33 Willemse A. Canine atopic disease: investigations of eosinophils and the nasal mucosa. Am J Vet Res 1984; 45 (09) 1867-1869
• 34 Schnabl B, Bettenay SV, Dow K. et al. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec 2006; 158 (03) 81-85
• 35 Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax Ausg K Kleintiere Heimtiere 2014; 42 (03) 167-173
• 36 Lian TM, Halliwell RE. Allergen-specific IgE and IgGd antibodies in atopic and normal dogs. Vet Immunol Immunopathol 1998; 66(3 – 4): 203-223
• 37 Aalberse RC, Koshte V, Clemens JG. Immunoglobulin E antibodies that crossreact with vegetable foods, pollen, and Hymenoptera venom. J Allergy Clin Immunol 1981; 68 (05) 356-364
• 38 Altmann F. Coping with cross-reactive carbohydrate determinants in allergy diagnosis. Allergo J Int 2016; 25 (04) 98-105
• 39 Levy BJ, DeBoer DJ. A preliminary study of serum IgE against cross-reactive carbohydrate determinants (CCD) in client-owned atopic dogs. Vet Dermatol 2018; 29 (03) 243-e90
• 40 Mueller RS, Bettenay SV. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Am J Vet Res 2001; 62 (03) 307-310
• 41 Mueller RS, Veir J, Fieseler KV. et al. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis – a pilot study. Vet Dermatol 2005; 16 (01) 61-68
• 42 Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol 2001; 81(3 – 4): 363-383
• 43 Timm K, Mueller RS, Nett-Mettler CS. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis. Vet Dermatol 2018; 29 (02) 123-e49
• 44 DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Vet Dermatol 2016; 27 (02) 82-87 e23
• 45 Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: An effective and safe alternative route for canine atopic dermatitis. Schweiz Arch Tierheilkd 2016; 158 (09) 646-652
• 46 DeBoer DJ. The future of immunotherapy for canine atopic dermatitis: a review. Vet Dermatol 2017; 28 (01) 25-e6
• 47 Kawano K, Mizuno T. A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis. Vet Dermatol 2017; 28 (06) 583-e141
• 48 Olivry T, Paps JS, Dunston SM. Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2. Vet Dermatol 2017; 28 (02) 183-e40
• 49 Fischer N, Tarpataki N, Leidi F. et al. An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol 2018;
• 50 Wagner I, Geh KJ, Hubert M. et al. Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis. Vet Rec 2017; 181 (05) 118